238 related articles for article (PubMed ID: 32501183)
41. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
[TBL] [Abstract][Full Text] [Related]
42. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.
Sloan PA; Moulin DE; Hays H
J Pain Symptom Manage; 1998 Aug; 16(2):102-11. PubMed ID: 9737101
[TBL] [Abstract][Full Text] [Related]
43. [Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Ogawa J; Nakamura K; Iizuka K; Sekizuka M; Yamamoto K; Horiuchi R
Yakugaku Zasshi; 2009 Mar; 129(3):335-40. PubMed ID: 19252390
[TBL] [Abstract][Full Text] [Related]
44. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
45. Unusual case of transdermal fentanyl in cachexia.
Lam D; Kay S; Pickard J; Harrison S
BMJ Support Palliat Care; 2019 Dec; 9(4):363-364. PubMed ID: 30612090
[TBL] [Abstract][Full Text] [Related]
46. Transition From Continuous Infusion Fentanyl to Hydromorphone in Critically Ill Patients.
Kovacevic MP; Szumita PM; Dube KM; DeGrado JR
J Pharm Pract; 2020 Apr; 33(2):129-135. PubMed ID: 29996718
[TBL] [Abstract][Full Text] [Related]
47. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y
Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919
[TBL] [Abstract][Full Text] [Related]
48. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
[TBL] [Abstract][Full Text] [Related]
49. Opioid equianalgesic conversion: the right dose.
Brant JM
Clin J Oncol Nurs; 2001; 5(4):163-5. PubMed ID: 12690618
[TBL] [Abstract][Full Text] [Related]
50. Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
O'Bryant CL; Linnebur SA; Yamashita TE; Kutner JS
J Pain Palliat Care Pharmacother; 2008; 22(4):282-90. PubMed ID: 21923312
[TBL] [Abstract][Full Text] [Related]
51. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine.
Vielvoye-Kerkmeer AP; Mattern C; Uitendaal MP
J Pain Symptom Manage; 2000 Mar; 19(3):185-92. PubMed ID: 10760623
[TBL] [Abstract][Full Text] [Related]
52. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
53. Case report of severe bradycardia due to transdermal fentanyl.
Hawley P
Palliat Med; 2013 Sep; 27(8):793-5. PubMed ID: 23341102
[TBL] [Abstract][Full Text] [Related]
54. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
Shinjo T; Okada M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744
[TBL] [Abstract][Full Text] [Related]
55. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
[TBL] [Abstract][Full Text] [Related]
56. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
57. A Comparison of Institutional Opioid Equianalgesia Tools: A National Study.
Wen RY; Atayee RS; Edmonds KP
J Palliat Med; 2022 Nov; 25(11):1686-1691. PubMed ID: 35559657
[No Abstract] [Full Text] [Related]
58. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
Kornick CA; Santiago-Palma J; Khojainova N; Primavera LH; Payne R; Manfredi PL
Cancer; 2001 Dec; 92(12):3056-61. PubMed ID: 11753984
[TBL] [Abstract][Full Text] [Related]
59. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
[TBL] [Abstract][Full Text] [Related]
60. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial.
Wirz S; Wartenberg HC; Elsen C; Wittmann M; Diederichs M; Nadstawek J
Clin J Pain; 2006; 22(9):770-5. PubMed ID: 17057558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
